Association of serum amyloid A and prognosis in people with diabetes and COVID‐19: A retrospective cohort study

Abstract

Abstract Aims/Introduction Serum amyloid A (SAA) is an acute phase reactive protein that plays a vital role in the early diagnosis, risk prediction, efficacy observation and prognosis evaluation of infectious diseases. This study aimed to assess the association between SAA levels and the prognosis of patients with coronavirus disease 2019 (COVID‐19) and diabetes. Materials and Methods We carried out this retrospective cohort study from March 2022 to May 2022. The population was stratified by tertiles of SAA levels: low (36 mg/L). The primary outcome was whether the patient developed severe COVID‐19, and secondary outcomes included the need for invasive mechanical ventilation and length of hospital stay. Logistic regression analyses were carried out to identify risk factors affecting the prognosis of patients with COVID‐19 and diabetes. Results We analyzed 910 diabetes patients with COVID‐19. The median age of the patients was 69 years, and 52.3% were men. As SAA levels increased, the proportion of severe COVID‐19 (6.3% vs 7.3% vs 22.8%, P 36 mg/L further increased the odds ratio to 4.423 (P 36 mg/L remained an independent risk factor for the development of severe COVID‐19 (adjusted odds ratio 3.038, P < 0.001). Conclusions SAA levels are strongly associated with poor prognosis in patients with COVID‐19 and diabetes.

Keywords

• COVID‐19
• Diabetes
• Serum amyloid A